Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: A preliminary report of three cases

Modern Rheumatology

Volumn 22, Issue 1, 2012, Pages 94-99

  Tamaki, Zenshiro ^a   Asano, Yoshihide ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Kawashima, Tomohiko ^a   Tomita, Manabu ^a   Kinugawa, Koichiro ^a   Nagai, Ryozo ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiopathy; Fli1; Imatinib mesylate; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

BERAPROST; BOSENTAN; IMATINIB; PROSTACYCLIN; SILDENAFIL;

ADULT; AGED; ARTICLE; BLEEDING; CASE REPORT; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; JOINT CONTRACTURE; JOINT MOBILITY; LOW DRUG DOSE; MALE; MUSCULOSKELETAL PAIN; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RASH; RAYNAUD PHENOMENON; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TREATMENT DURATION; VASCULAR DISEASE;

AGED; CONTRACTURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; NAILS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANGE OF MOTION, ARTICULAR; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

EID: 84861479141     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0472-1     Document Type: Article

References (24)

1. Asano Y. Future treatments in systemic sclerosis. J Dermatol. 2010;37(1):54-70.
2. ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol. 2009;98(4): 265-7.
3. Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J. 2010;51(4):272-6.
4. Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly. 2010;140:w13050.
5. Denton CP, Nihtyanova SI, Varga J, et al. Comparative analysis of change in modified Rodnan skin score in patients with diffuse systemic sclerosis receiving imatinib mesylate suggests similar disease course to matched patients receiving standard therapy. Arthritis Rheum. 2010;62(S10): Abstract 566.
6. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011.
7. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56(1): 311-22. (Pubitemid 46106205)
8. Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum. 2004;50(5):1578-85. (Pubitemid 38608080)
9. Bhattacharyya S, Ishida W, Wu M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene. 2009;28(10):1285-97.
10. Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008;3(1):e1452.
11. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010;176(4):1983-98.
12. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 1999; 42(5):930-41. (Pubitemid 29215003)
13. Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003;163(2):571-81. (Pubitemid 36909419)
14. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54(7):2271-9. (Pubitemid 44051084)
15. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol. 2009;29(2):425-34.
16. Asano Y, Trojanowska M. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol. 2009;29(7):1882-94.
17. Asano Y, Czuwara J, Trojanowska M. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem. 2007;282(48):34672-83. (Pubitemid 350232412)
18. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-51.
19. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother. 2003;4(6):963-71. (Pubitemid 36722486)
20. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709-18.
21. Fietta A, Bardoni A, Salvini R, et al. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res Ther. 2006;8(6):R160.
22. Kucharz EJ, Grucka-Mamczar E, Mamczar A, Brzezinska-Wcislo L. Acute-phase proteins in patients with systemic sclerosis. Clin Rheumatol. 2000;19(2):165-6. (Pubitemid 30236152)
23. Azuma M, Nishioka Y, Aono Y, et al. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med. 2007; 176(12):1243-50. (Pubitemid 350256478)
24. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008; 47(5):735-7. (Pubitemid 351619226)